Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II study of CETP inhibitor obicetrapib meets primary endpoint

July 29, 2021

MMV-688533 shows excellent single-dose efficacy in P. falciparum-infected mouse model

July 29, 2021

ISIS-814907 well tolerated in first-in-human study in mild Alzheimer's disease patients

July 29, 2021

New serine-protein kinase ATM inhibitors described by Medshine Discovery

July 29, 2021

Vonafexor meets primary endpoint in the phase IIa LIVIFY study in patients with NASH

July 29, 2021

FDA authorizes phase II study of autologous adipose-derived mesenchymal stem cells in MS

July 29, 2021

First patients dosed in new studies of Xpovio in melanoma and myelofibrosis

July 29, 2021

Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent PD-1/PD-L1 inhibitors

July 29, 2021

New RORgammaT agonists identified at Sunshine Lake Pharma

July 29, 2021

Chengdu Baiyu Pharmaceutical presents new tetrahydrocannabinol derivatives

July 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...